Treatment of seasonal affective disorders by Praschak-Rieder, Nicole & Willeit, Matthäus
easonal affective disorder (SAD),as originally
described in 1984,
1 is a condition characterized by the
annual recurrence of depressive episodes in fall and win-
ter followed by remission of depressive symptoms in
spring and summer.
1 Patients with SAD have to meet
diagnostic criteria for major depression, recurrent, or
bipolar disorder.In the latest version of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV),
SAD is listed as a specifier of either bipolar or recurrent
major depressive disorder, with a seasonal pattern of
major depressive episodes.
2 Subsyndromal SAD is a dis-
order with similar but milder symptoms that do not
grossly disrupt patients social and occupational func-
tioning.
3 The four central features characterizing SAD
are listed in Table I. Patients with SAD have the usual
symptoms of depression, including low mood, lack of
drive, decreased concentration, and reduced interest.
Typically,many SAD patients also tend to have a specific
symptom cluster consisting of the so-called reverse veg-
etative or atypical depressive symptoms.These symptoms
include increased sleep (70%-90% of SAD patients),
increased appetite (70%-80%), carbohydrate craving
(80%-90%),and weight gain (70%-80%).
4
Pathophysiology
The etiology of SAD remains unclear.It is thought that
the decreasing daylight period as winter approaches trig-
gers depressive episodes in individuals vulnerable to
SAD.However,although bright light exposure is used in
the treatment of SAD,no causal relation can be drawn
between the occurrence of SAD and the shortage of light
in fall and winter.Patients with SAD may be sensitive to
factors that are common to various forms of recurrent
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Treatment of seasonal affective disorders
Nicole Praschak-Rieder, MD; Matthäus Willeit, MD
S
Seasonal affective disorder (SAD) is a subform of major
depressive disorder, recurrent, or bipolar disorder with a
regular onset of depressive episodes at a certain time of
year, usually the winter. The treatment of SAD is similar to
that of other forms of affective disorder, except that
bright light therapy is recommended as the first-line
option. Light therapy conventionally involves exposure to
visible light of at least 2500 lux intensity at eye level. The
effects of light therapy are thought to be mediated exclu-
sively by the eyes, not the skin, although this assumption
has not yet been verified. Morning light therapy has
proven to be superior to treatment regimens in the
evening. Response rates to light therapy are about 80%
in selected patient populations, with atypical depressive
symptoms being the best predictor of a favorable treat-
ment outcome. Data from randomized, controlled trials
suggest that antidepressants are effective in the treat-
ment of SAD. Three double-blind, placebo-controlled tri-
als have been conducted showing promising results for
the selective serotonin reuptake inhibitors (SSRIs) sertra-
line and fluoxetine, as well as for moclobemide, a
reversible inhibitor of monoamine oxidase A. 
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ven by endogenous annual rhythms and characterized by
an imbalance of indoleamines,serotonin,and melatonin,
as well as catecholamines,over the year.
Light therapy
Bright light therapy (BLT) has become a first-line clinical
standard for treatment of SAD (Table II).The use of BLT
as a therapy for SAD evolves directly out of neuroscience.
In the early 1980s,knowledge that light could shift circa-
dian and seasonal rhythms in animals,together with the
heuristic idea of extending daylight during the winter
months, led to the first clinical study on BLT in SAD.
1
Since then,numerous studies have not only proven its effi-
cacy,but also greatly refined our knowledge on treatment
strategies,thereby allowing for astonishingly high response
rates of 80% in selected patient populations.
5 BLT is safe,
effective,and it has few and benign side effects.It is gen-
erally well accepted by the patients,
6 and indications other
than SAD,eg,disturbances of circadian rhythm due to jet
lag or shift work,
7,8 circadian-phase–related disturbances
in dementia,
9,10 sleep disorders,
11,12 and nonseasonal affec-
tive disorders,
13-15 are expanding research fields.
Efficacy
The first controlled clinical trial
1 already showed the ben-
eficial effects of light against symptoms of SAD. Since
then, more than 60 controlled studies and two meta-
analyses
16,17 have shown the efficacy of this treatment.
Using stringent criteria,the meta-analysis of Terman et
al
16 found remission rates of up to 67% of patients with
milder depression and up to 40% of more severely
depressed patients.These benefits were seen as early as
1 week after beginning treatment. However, it is now
known that improvement may sometimes be seen as late
as 2 to 4 weeks after beginning BLT.
18
The obvious obstacles in the search for plausible placebos
and “blinded” designs for studying the efficacy of BLT
have led to concerns about the adequacy of control con-
ditions.Early studies mostly used dim-light of an intensity
of 300 lux or less,delivered through a light source other-
wise identical to that used in the active condition (mostly
light of 2500 lux intensity).As it was still possible to dis-
tinguish between the bright and dim-light conditions,these
studies have been questioned as to whether they measured
real biological effects and whether they could reliably sep-
arate a true antidepressant effect from placebo effects.
However,fantasy and creativity of researchers in the field
has led to further studies,which now unequivocally prove
that light is an active biological agent with antidepressant
effects in SAD.Some of these studies used (deactivated)
negative ion generators as placebo condition.
18-20 Like a
light box,the negative ion generator is a device,has a plau-
sible mechanism of antidepressant action,and requires the
subject to sit beside it.Light had the better antidepres-
sant effect and produced significantly more remissions,
although expectations were equal for both conditions.
Interestingly enough,high doses of negative ions do seem
to have an antidepressant effect as well.
20
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Table I. Features of seasonal affective disorder (SAD).
Recurrent major depressive episodes that start around the
same time each year (eg, fall and winter) and end around
the same time each year (eg, spring and summer)
Full remission of symptoms during the unaffected period of
the year (eg, summer)
Over the lifetime course of the illness, there are relatively
more seasonal depressive episodes than nonseasonal
episodes
Seasonal depressive episodes occur in at least 2 consecutive
years
Table II. Guidelines for bright light therapy (BLT).
Light therapy is an effective first-line treatment for seasonal
affective disorder
A fluorescent light box with light intensities greater than
2500 lux is the preferred device for light therapy
An optimal starting dose for light therapy is 10 000 lux for
30 min/day
Light boxes emitting 2500 lux are effective with a treatment
duration of 2 h/day
Morning light is more effective than evening light. Patients
should be encouraged to undergo light therapy as early as
possible (eg, before/during breakfast). However, evening
light may be effective for some patients
Many patients will respond as early as after 1 week.
However, in some cases a response may occur after only 2 to
4 weeks
If there is no sufficient response after two treatment weeks,
the dose should be doubled to 30 min in the morning plus
30 min in the evening
If this regimen does not lead to sufficient improvement,
consider adding a pharmacological treatment (best evi-
dence available for serotonin reuptake inhibitors)Another challenge for efficacy studies on light therapy is
the “light-noise”inevitably encountered in a normal liv-
ing environment.Depending on weather conditions,out-
door light intensities can easily surmount the intensities
delivered by a light box,even in the winter.This has been
compared to a study trying to prove the superiority of an
antidepressant drug over placebo,with antidepressants
occasionally delivered through the drinking water to all
study subjects.
21 Nevertheless,today there is sound evi-
dence showing that antidepressant effects of light in SAD
are real biological treatment effects.
16,20,22
Dose
Earlier studies have mostly used light intensities of 2500
lux.This is much more than the typical indoor illumina-
tion,ranging from 100 lux in average rooms to about 500
lux in brightly illuminated ones.Outdoor light intensities
greatly vary with weather conditions ranging from about
2000 lux on a rainy winter day to 10 000 lux or more
(usually 50 000 to 300 000 lux) in direct sunshine.Today,
light treatment with intensity of 10 000 lux has become
clinical standard.One great advantage of higher inten-
sity light is that it allows for shorter exposure times.
Current clinical guidelines recommend beginning treat-
ment with 10 000 lux for 30 min in the morning.
23
Nevertheless,intensities of 2500 lux have shown to have
antidepressant effects when applied for 2 h daily.
Timing
A further finding that emerged from BLT studies is the
superiority of morning light over light administered in
the evening.
16,20,22 By further refining timing of light
administration in relationship to the position of the cir-
cadian phase,Terman and coworkers achieved remission
rates up to 80% in selected patient populations.
5 They
were able to show that response to BLT critically
depends on time of delivery relative to the position of the
circadian phase as determined by the onset of melatonin
secretion in the evening (dim-light melatonin onset).The
study suggests that the ideal therapy time is around 8.5 h
after melatonin onset.
Although the superiority of morning light in the majority
of patients with SAD had been demonstrated before,
16,20,22
Terman and colleagues showed that,for clinical purposes,
circadian phase position can simply and reliably be deter-
mined by administration of a modified version Horne-Öst-
berg morningness-eveningness scale.
24 The authors also
provide an online-questionnaire
25 together with recom-
mendations for individually optimized light therapy tim-
ing as based on morningness-eveningness or individual cir-
cadian phase position.In summary,now there is sufficient
evidence that light administered in the early morning is
superior to evening light.
Dawn stimulation
Many patients with SAD experience markedly increased
duration of sleep during the winter months.
1,4,26 Usually,
most of these patients have to force themselves out of bed
during the weekdays despite feeling excessively drowsy.
Dawn stimulation is a form of light therapy involving grad-
ually increasing bedside light in the morning before awak-
ening.
27 Dawn stimulation has shown to improve symp-
toms of SAD compared with placebo light signals.
28,29 In
addition,dawn stimulation appears to be effective in ame-
liorating the difficulty awakening and morning drowsiness
in SAD.
30 In a comparison study,dawn stimulation using
100 to 300 lux for 60 to 90 min every morning improved
symptoms of SAD similarly to light therapy using 1500 to
2500 lux for 2 h every morning.
31
Adverse effects
The adverse effects of light therapy include headache,eye-
strain,nausea,and agitation.
32,33 Usually,adverse effects are
mild and subside spontaneously or with dose reduction.
Bright light in the evening may be associated with sleep
disturbances,and,occasionally,hypomania may arise dur-
ing BLT.
33 However, subjective benefits of light consis-
tently outweigh its adverse effects.
32,33 Altogether, it
remains questionable whether the frequency of these
symptoms under BLT significantly exceeds the frequency
of side effects seen under placebo conditions.
Risks
There are no absolute contraindications for light therapy.
23
Animal studies suggest increased risk for retinal damage
with lithium,β-blockers,tricyclic antidepressants,and tryp-
tophan.However,no such interactions have been reported
in humans,and there is no evidence that light therapy is
associated with ocular or retinal damage in humans.
Patients with severe ophthalmological conditions or
patients taking photosensitizing medication should have
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therapy.However,it is important that the UV spectrum is
filtered out of the therapeutic light source.
Although suicidality is commonly regarded as being rather
infrequent in SAD,our own group has reported severe sui-
cidal ideation and suicide attempts in three patients after
the initiation of light therapy.
34All three patients had sui-
cidal thoughts before light therapy was started.As always
when dealing with depressed patients,patients with SAD
should be carefully assessed for suicidality before light
therapy,and therapy outcome should frequently and reg-
ularly be evaluated by health care professionals.
Treatment predictors
Atypical depressive symptoms,specifically hyperphagia,
hypersomnia,and carbohydrate craving,seem to be asso-
ciated with favorable response to BLT.
35,36Younger age
also seems to predict a good response,
37 while comorbid
personality disorders seem to compromise the response
to BLT.
38,39
Mechanism of action
Theories on the mechanism of action of BLT are closely
connected to what is known about the pathogenesis of
SAD.
40 Two main—mutually not exclusive—theories
have been raised by researchers in the field:one concen-
trates on the evidence for reduced serotonin neuro-
transmission in SAD,the other theory relates light ther-
apy–induced improvement to corrections of altered
circadian rhythms during depression in SAD.
Serotonin
Several lines of evidence suggest an alteration in serotonin
neurotransmission in SAD.
40-42A keystone of the serotonin
hypothesis on the mechanism of action of light therapy is
the finding that lowering brain serotonin by tryptophan
depletion leads to a transient depressive relapse in patients
with SAD who are in light therapy–induced remission.
43
In line with this theory is the beneficial effect of selective
serotonin reuptake inhibitors (SSRIs) in SAD.Although
there is evidence for a seasonal variation in serotonin
neurotransmission,
44 and although there seems to be a
close relationship between brain serotonin and atypical
depressive symptoms,
41 serotonergic alterations are not
specific for the pathogenesis of SAD or the antidepres-
sant action of light.They rather seem to constitute a path-
way common to depressive syndromes and their treat-
ment in general.
Circadian phase shifts
More specific for SAD are the theories concerning alter-
ations in circadian and circannual rhythms.Neurons of the
hypothalamic suprachiasmatic nucleus (SCN) act as the
main “zeitgeber”in the mammalian organism.Having an
intrinsic near to 24-h rhythm,they are also known as the
“internal clock.”These neurons are reset by environmen-
tal light,and they are believed to be the main determinant
for the position of the circadian phase.Several body func-
tions,such as hormonal rhythms,including nocturnal mela-
tonin secretion,sleep,or eating behavior,are subjected to
a specific circadian rhythm.The best studied marker for
the position of the circadian phase is the onset of mela-
tonin secretion by the pineal gland.
45 In humans,the begin-
ning of melatonin secretion occurs in the evening,usually
between 1 and 2 h before falling asleep.Light can shift the
position of the circadian phase,and amount and direction
of that shift greatly depend on the time of light exposure:
light in the evening leads to a phase delay (eg,melatonin
onset occurs later),morning light advances the circadian
phase.
20,22
Early theories on the pathogenesis of SAD held that a
delay in the circadian phase was responsible for the
appearance of SAD symptoms.
46 Although the phase-
delay hypothesis on the pathogenesis of SAD did not
hold up,as there does not seem a consistent pattern of
phase alterations in SAD,recent work has shown the cir-
cannual variation in circadian phase to be altered in
patients with SAD when compared with healthy control
subjects.
47 Recent work by Terman and colleagues
showed a correlation between light-induced changes in
the “phase angle”(the relationship between the circadian
phase as measured by melatonin onset and, eg, sleep
onset) and antidepressant response to light in SAD.
5
Practical issues
Sufficient and clear instructions to patients are critical for
a satisfactory treatment response. Patients should be
informed that the beneficial effects of light are not endur-
ing, ie, that a relapse is to be expected after a few days
when treatment is discontinued.Although one study
48 sug-
gested a transcutaneous effect of light on melatonin secre-
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49,50 It is so far
safe to state that the antidepressant effect of light is medi-
ated by the eye.The patient therefore needs to make sure
that light of sufficient intensity meets the eye.Light pro-
jection does not need to be foveal,ie,it is not necessary to
look directly into the light source.The ideal is an angle of
about 30° to 60° to let enough light meet the eye and allow
for the patient to, for example, read or eat during light
therapy.The intensity of light critically depends upon the
distance from the light source.Light boxes should be pow-
erful enough to deliver an intensity of about 10 000 lux at
a distance of 60 to 90 cm.If the light box is less powerful,
treatment time should be expanded (see above).Patients
should be encouraged to seek exposure to environmental
light on sunny days. Sunlight has much higher intensity
than light delivered by a light therapy device (see above).
Despite the fact that light therapy is now recommended
as a treatment of choice for SAD,only in Switzerland has
the economic argument that in the long run, light is
cheaper than drugs, attained government endorsement
and mandatory reimbursement by medical insurance.
51
The fact that there is no reimbursement for light therapy
has been widely criticized by patients with SAD,their rel-
atives,and experts in the field of SAD.
52 Case reports on
SAD patients resistant to several antidepressants, but
finally responsive to light therapy illustrate that,although
depressive symptoms may often be only moderate,SAD
can lead to severe impairment in occupational and social
functioning and can precipitate catastrophic life events.
52,53
Pharmacotherapy
Although light therapy is recommended as the first-line
option for SAD,some patients do not experience suffi-
cient relief of depressive symptoms with light.BLT can
then be supplemented with antidepressant drugs.Other
patients with SAD feel unable to integrate light therapy
into their daily routine,or other logistical difficulties in
administering light therapy are present.The evidence of
SAD being associated with a dysfunction in brain sero-
tonin systems has guided the search for promising phar-
macological treatments of SAD. Data emerging from
multicenter placebo-controlled trials has led to the rec-
ommendation of the SSRIs sertraline and fluoxetine as
first-line treatments of SAD.Other antidepressant com-
pounds,like monoamine oxidase inhibitors,dopaminer-
gic and noradrenergic agents,melatonin,β-blockers as
melatonin antagonists,herbs,and nutritional supplements
like L-tryptophan and vitamin D have been investigated
in small studies.The efficacy of these medications has not
yet been proven in SAD.Open trials,controlled studies,
and placebo-controlled studies in SAD are listed in
Tables III to V.
54-75 New pharmacological agents are of
potential value in the treatment of SAD, for example,
agomelatine (Valdoxan).This new dual melatonergic and
specific serotonergic antidepressant has been shown to
be efficient in the treatment of major depression
76:i t
exhibits a specific core action on circadian rhythms,and
therefore could be of particular value in the treatment of
SAD.More specific studies are underway to more obtain
information about its activity in SAD.
Open studies
A survey of open studies in SAD is given in Table III.
54-61
There is some suggestion from pilot data with small sam-
ple sizes that serotonergic agents like fluoxetine,citalo-
pram, and trazodone may be treatment options for
SAD.
54,57Tranylcypromine,a nonselective monoamine oxi-
dase inhibitor was effective in the treatment of 14 patients
leading to an average 91% reduction in depressive symp-
toms within 4 weeks of initiation of treatment.
55A study
in 20 patients indicates that St John’s wort (Hypericum
perforatum) may be helpful in treating SAD.An add-on
therapy with bright light in 10 of these patients treated
with hypericum did not lead to a significantly better treat-
ment outcome.
59Two studies in 6 patients each report ben-
eficial effects of the benzodiazepine alprazolam.
56,60A 6-
week open trial investigating efficacy and tolerability of
reboxetine,a selective noradrenaline reuptake inhibitor,
led to rapid full remission of depressive symptoms in 11
out of 16 patients.
61A rapid relief of preexistent severe
atypical symptoms was observed in 9 patients within the
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Table III. Open studies of pharmacotherapy of seasonal affective disorder
(SAD).
54-61
Authors Number Medication
of patients
Jacobsen et al,
54 1989 n=3 Fluoxetine, trazodone
Dilsaver and Jaeckle,
55 1990 n=14 Tranylcypromine
Teicher and Glod,
56 1990 n=6 Alprazolam
Wirz-Justice et al,
57 1992 n=1 Citalopram
Lingjaerde et al,
58 1993 n=5 Moclobemide
Martinez et al,
59 1994 n=20 Hypericum
Yamadera et al,
60 2001 n=6 Alprazolam
Hilger et al,
61 2001 n=16 Reboxetinefirst week of treatment.This finding is of pathophysio-
logical interest since,so far,atypical depressive symptoms
like increased appetite,carbohydrate craving,and hyper-
somnia have been strongly associated with a dysfunction
in brain serotonin systems.
Controlled studies
Controlled studies of pharmacotherapy in SAD are pre-
sented in Table IV.
62-66A study by Ruhrmann et al com-
paring the SSRI fluoxetine and light therapy in 40
patients with SAD found no significant difference in
treatment outcome between the groups, but a faster
onset of antidepressant action in the light therapy
group.
63
Because SAD is prevalent in winter when vitamin D
stores are typically low, and because light therapy
includes wavelengths that allow the skin to produce vit-
amin D,the potential role of vitamin D in SAD has been
investigated in a small pilot study.
65 Vitamin D was
reported to lead to a greater improvement of depressive
symptoms than light therapy.However,no difference in
vitamin D levels has been observed between patients
with SAD and healthy subjects,
70,77 and the antidepressant
effect of light therapy has been shown to be independent
of changes in vitamin D levels.
77 So far,any benefits of
vitamin D on SAD remain unproven.In two small,pre-
liminary trials,4 to 6 g daily doses of the amino acid L-
tryptophan,the precursor of serotonin,were as effective
as light therapy.
62,64 In a postal survey using an 11-item
rating scale,301 patients with SAD treated with hyper-
icum at 300 mg three times daily for 8 weeks were asked
to report changes in their symptoms.
66 Of these patients,
133 used additional light therapy. Significant overall
improvement was reported in both treatment groups.
Improvement in sleep was greater in the hypericum and
light therapy group.However,double-blind research is
needed to confirm the usefulness of hypericum (St John’s
wort) for treating SAD.
Placebo-controlled studies
Table V
58,67-75 presents placebo-controlled studies of phar-
macotherapy in SAD.The best evidence for efficacy of
antidepressants in SAD comes from studies of SSRIs.
Multicenter,double-blind,randomized studies of fluox-
etine and sertraline confirm that these medications are
effective in the treatment of SAD.In the fluoxetine study
(68 patients),significant improvement in mood was pre-
sent in both fluoxetine and placebo-treated patients at
termination of the study.However,there was significant
superiority of fluoxetine over placebo in the clinical
response rates (59% versus 34%,respectively).
71 In the
sertraline study (187 patients),a significant superiority to
placebo in both clinical response rates (62% versus 46%,
respectively) and depression scores was found.Although
they have been widely cited,the data from the sertraline
study have only been published as an abstract so far.
78A
double-blind study by Lingjaerde et al
58 investigating the
efficacy of moclobemide, a reversible inhibitor of
monoamine oxidase A, versus placebo over 14 weeks
found no significant difference in depression scores
between groups at study termination.However,within
the first week of treatment,patients in the moclobemide
group, but not in the placebo group, had a significant
reduction in atypical depression symptoms.Testing the
Clinical research
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Table IV. Controlled studies of pharmacotherapy of seasonal affective disorder (SAD).
62-66 LT, light therapy.
Authors Number of patients Medication and study design Outcome
McGrath et al,
62 1990 n=13 L-Tryptophan and LT  No significant difference
versus L-tryptophan alone
Ruhrmann et al,
63 1998 n=40 Fluoxetine versus LT No significant difference, 
but faster onset of antidepressant 
action in LT group
Ghadirian et al,
64 1998 n=13 L-Tryptophan versus LT,  No significant difference
crossover study
Gloth et al,
65 1999 n=15 Vitamin D versus LT Vitamin D superior to LT
Wheatley,
66 1999 n=168 Hypericum and LT  Significant improvement in both 
versus hypericum alone groups, improvement in sleep greater 
in hypericum and LT groupTreatment of seasonal affective disorders - Praschak-Rieder and Willeit  Dialogues in Clinical Neuroscience - Vol 5 . No.4 . 2003
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hypothesis that a dopaminergic deficiency plays a role in
the pathophysiology of SAD, Oren et al conducted a
small study investigating the efficacy of levodopa plus
carbidopa as a treatment for SAD.
68 No differences to
placebo were found in the rates of response.The mela-
tonin hypothesis of SAD was tested in two studies using
the β-blockers atenolol
67 and propanolol
69 to suppress
melatonin secretion.No difference in antidepressant effi-
cacy was found between atenolol and placebo.Propanolol
was superior to placebo in preventing a depressive relapse
in patients with SAD who had previously responded to an
open treatment with propanolol.Supplementation with
melatonin has shown to be ineffective in patients with
SAD when taken at night or in the morning.
79 Melatonin
has also been reported to even reverse the benefits of
light therapy.
80 However, a small pilot study with low
doses of melatonin in the afternoon showed a significant
decrease in depression ratings compared to placebo.
72
The authors argue that a replication of this finding in an
adequate sample with documentation of expected phase
shifts would substantially support the phase shift hypoth-
esis of SAD.A recent 1-year pilot study
73 aimed at inves-
tigating possible advantages of combining light therapy
with the SSRI citalopram.No significant group difference
was found during the initial 10-day light therapy period.
However,during the follow-up period depression ratings
were significantly lower in the citalopram group com-
pared with the placebo group.The authors conclude that
light therapy with continued SSRI treatment may be a
useful strategy to achieve beneficial long-term effects in
patients with SAD.A study by Lingjaerde et al
74 testing
the hypothesis that Ginkgo biloba extract may prevent
the symptoms of winter depression in patients with SAD
yielded negative results.In a recent study metergoline,
a nonspecific serotonin antagonist,did not demonstrate
a sustained significant effect on mood compared with
placebo.
75
General management issues
Since there is little evidence comparing light therapy with
antidepressant medication,the choice between these alter-
natives relies on individual assessment of risks and bene-
fits.
23 Generally, light therapy is very well accepted by
patients.Availability and costs of a light therapy device are
sometimes limiting factors,as is the time patients need to
commit for daily light therapy.However,BLT should be
considered first-line treatment for moderately depressed
Table V. Placebo-controlled studies of pharmacotherapy of seasonal affective disorder (SAD).
58,67-75 LT, light therapy.
Authors Number of patients Medication and study design Outcome
Rosenthal et al,
67 1988 n=19 Atenolol versus placebo No significant difference
Lingjaerde et al,
58 1993 n=34 Moclobemide versus placebo No significant difference, but 
significant reduction of atypical 
symptoms in moclobemide group
Oren et al,
68 1994 n=25 Levodopa + carbidopa  No significant difference
versus placebo
Schlager,
69 1994 n=23 Propanolol versus placebo Significantly higher relapse rates in 
placebo group
Oren et al,
70 1994 n=27 Vitamin B12 (cyanocobalamine)  No significant difference
versus placebo
Lam et al,
71 1995 n=78 Fluoxetine versus placebo No significant difference, higher 
response rate in fluoxetine group
Lewy et al,
72 1998 n=10 Melatonin versus placebo Melatonin superior to placebo
Thorell et al,
73 1999 n=8 LT and citalopram  No significant difference between 
versus LT and placebo citalopram and placebo during LT; 
after LT citalopram superior to placebo
Lingjaerde et al,
74 1999 n=27 Ginkgo biloba versus placebo No significant difference; gingko 
significant more effective in 
preventing new depressive episodes
Turner et al,
75 2002 n=16 Metergoline versus placebo No significant differenceClinical research
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Tratamiento de los trastornos afectivos 
estacionales
El trastorno afectivo estacional (TAE) es un subtipo
del trastorno depresivo mayor recurrente o del tras-
torno bipolar, con una aparición regular de episodios
depresivos en cierta época del año, especialmente en
invierno. El tratamiento del TAE es similar al de otros
tipos de trastorno afectivo, excepto que la terapia
con luz brillante se recomienda como opción de pri-
mera línea. Convencionalmente la terapia lumínica
se refiere a la exposición a luz visible de al menos
2500 lux de intensidad a nivel del ojo. Se piensa que
los efectos de la fototerapia son mediados exclusi-
vamente por los ojos, no por la piel, aunque esta
hipótesis no ha sido aun verificada. La terapia lumí-
nica matinal ha probado ser superior a las aplicacio-
nes vespertinas. Los porcentajes de respuesta a la
fototerapia son cercanos al 80% en poblaciones
seleccionadas de pacientes y los síntomas depresivos
atípicos son el mejor predictor de una evolución
favorable al tratamiento. Datos de ensayos contro-
lados, randomizados sugieren que los antidepresivos
son efectivos en el tratamiento del TAE. Se han rea-
lizado tres estudios doble ciego, controlados con pla-
cebo que han mostrado resultados promisorios para
los inhibidores selectivos de la recaptación de sero-
tonina (ISRS) sertralina y fluoxetina, y también para
moclobemida, un inhibidor reversible de la monoa-
mino-oxidasa A.
Traitement du trouble affectif saisonnier
Le trouble affectif saisonnier (TAS) représente un
sous-groupe des troubles dépressif majeur récurrent
ou bipolaire et se caractérise par l’installation régu-
lière d’épisodes dépressifs à certaines périodes de
l’année, généralement en hiver. Le traitement du
TAS est semblable à celui des autres formes de trou-
bles affectifs, si ce n’est que la photothérapie à
lumière vive est recommandée en première inten-
tion. La photothérapie conventionnelle implique
l’exposition à une lumière du spectre visible d’une
intensité supérieure à 2 500 lux au niveau de l’œil.
Les effets de la photothérapie sont considérés
comme médiés exclusivement par les yeux et non la
peau, bien que cette hypothèse n’ait pas encore été
vérifiée. La photothérapie matinale s’est avérée
supérieure au schéma thérapeutique vespéral. Les
taux de réponse à la photothérapie sont d’environ
80 % dans des populations sélectionnées de patients,
les symptômes dépressifs atypiques étant le meilleur
facteur prédictif d’évolution thérapeutique favora-
ble. Des données issues d’études randomisées,
contrôlées, suggèrent que les antidépresseurs sont
efficaces dans le traitement du TAS. Trois études en
double aveugle, contre placebo, ont été réalisées,
montrant des résultats prometteurs pour les inhibi-
teurs sélectifs de la recapture de la sérotonine (ISRS),
la sertraline et la fluoxétine, ainsi que pour un inhi-
biteur de la monoamine oxydase sélectif A (IMAO
sélectif A), le moclobémide.
patients and patients with prominent atypical depressive
symptoms.Generally,light therapy alone or in combina-
tion with antidepressants should be given for the duration
of the dark time of year,ie,until April or May in the north-
ern hemisphere.A trial of light therapy should last at least
2 to 4 weeks.A trial of antidepressants should last 4 to 6
weeks. Light therapy and medication trials should be
applied sequentially,as combining them from the begin-
ning on will lead to a loss of information about which
treatment is beneficial,or which treatment is causing side
effects.A combination of both treatments should be con-
sidered if there is insufficient response to either pharma-
cological or light treatment.If a depressive episode is resis-
tant to the combination of BLT and an antidepressant,
options are lengthening light treatment time,raising the
dose of the antidepressant,or switching to a drug of a dif-
ferent class.Although there are no specific data available
for SAD, treatment should follow algorithms for treat-
ment-resistant depression if a sufficient response still can-
not be achieved.Pharmacological augmentation strategies,
electroconvulsive therapy, or sleep deprivation proce-
dures
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